Navigation Links
DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
Date:10/26/2013

Dallas, TX (PRWEB) October 26, 2013

The prescription drug resource center DrugRisk.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recently published study identified the drug as the most often reported for serious side effects like internal bleeding*.

The news comes on the same day as a federal court disclosed the number of lawsuits alleging internal bleeding injuries has again grown**.

The DrugRisk center is a free resource for those taking popular prescription drugs. By providing the latest product recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.

Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding.

The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin***. Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from Pradaxa bleeding than from warfarin bleeding****. A study this year from the Netherlands also suggested patients taking blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding*****.

Now. DrugRisk has learned that the latest study from the Institute for Safe Medication Practices found Pradaxa ranked highest for number of complaints to the FDA last year, with 683 reports of bleeding*.

A growing number of patients have also filed a Pradaxa lawsuit alleging internal bleeding, leading to the consolidation of cases in a special federal multidistrict litigation court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

DrugRisk has added the latest court records from the Judicial Panel on Multidistrict Litigation, which show the number of cases filed has increased from 1,470 on September 11th to 1,643 on October 17, a rise of nearly 12% in less than a month**.

Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*Institute for Safe Medication Practices, 10/17/13; ismp.org/quarterwatch/pdfs/2012Q4.pdf
**Judicial Panel on Multidistrict Litigation, 10/17/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-October-17-2013.pdf
***FDA, 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
****Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
*****Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext

Read the full story at http://www.prweb.com/releases/2013-pradaxa/gastrointestinal-bleeding/prweb11271909.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Alerts of New Rise In Mirena Lawsuits Alleging Uterine Damage
2. DrugRisk Updates with Latest Case Numbers Since Januvia Lawsuits Sent to MDL Court
3. DrugRisk Update: Byetta Lawsuits Headed to Special Federal Court
4. DrugRisk Update: Januvia Lawsuits Alleging Cancer Headed to Federal Court
5. DrugRisk Update: Latest Court Order Moves Mirena Lawsuits Forward
6. DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
7. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
8. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
9. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
10. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
11. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: